Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

The meeting cancellation came one day before the CDC issued its weekly MMWR report, a scientific update on the latest ...

Most people will recover from viruses like the flu, COVID, and RSV without medical care, but some patients might need a trip ...

The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

A recent modification to the contract would have allowed Vaxart to invoice BARDA for the remaining $230 million or so for ...

Adults aged more than 70 who received more prescriptions for nirmatrelvir-ritonavir did not show decreased rates of ...

In a small study, Yale researchers have found "differences in immune profiles" among those who have rare reaction to the ...

FDA's reasoning appears to center on a belief that COVID-19 treatment immunobridging analyses for a monoclonal antibody (mAb) must meet a standard of superior antiviral activity rather than equivalent ...

A new analysis of health data from Ontario, Canada, suggests that nirmatrelvir-ritonavir (Paxlovid) may provide limited benefit for vaccinated older adults with COVID-19, despite its previously proven ...

Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.

The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to ...